Summary The 5T4 oncofetal antigen is a 72 kDa glycoprotein defined by a monoclonal antibody raised against human placental trophoblast and is expressed in many different carcinomas but detected only at low levels in some normal epithelia. Immunohistochemical analysis of the patterns of expression in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumour cells and metastatic spread. The 5T4 antigen phenotype of 72 colorectal cancers has been compared with the clinical outcome of the patients in order to assess its relationship with prognosis. Forty per cent of tumours were 5T4 positive; the remainder were either unlabelled or exhibited stroma-associated labelling only. There was a significant correlation between 5T4 expression in the malignant cells and unfavourable course of disease (P<0.001). The 5 year survival with 5T4-positive tumours was 22% compared with 75% for patients with 5T4-negative tumours; median survival was 24 versus > 90 months respectively. Stratified analysis showed that 5T4 antigen tumour positivity was acting independently of each of stage, site of tumour, age or sex. There were significant differences in survival for patients with Dukes' B and C stage carcinomas (P = 0.001 and P = 0.034). The results suggest that in colorectal cancer immunohistochemical assessment of 5T4 expression may be useful in identifying patients at high risk for tumour recurrence and for whom additional treatment strategies might be most appropriate.
Colorectal carcinoma is one of the most common malignant diseases in the Western countries and is a leading cause of neoplastic mortality (American Cancer Society, 1990; King's Fund Forum, 1990; Silverberg et al., 1990 (Laurie et al., 1989; Moertel et al., 1990; Krook et al., 1991) . The identification of patient subgroups at high or low risk of tumour recurrence following surgery would be of practical importance given the toxicity, differential efficacy and high cost of the adjuvant treatment. Dukes' staging (Dukes, 1932) is still the best available prognostic indicator and dictates most therapeutic decisions. However, this classification does not give a complete separation of good and bad prognosis for the individual patient. Thus, approximately one-third of patients with a Dukes' B tumour will die from their disease, while one-third of patients with a Dukes' C tumour will become long-term survivors (Eisenberg et al., 1982 (Matturri et al., 1991; Witzig et al., 1991; Tomoda et al., 1993) . Also, initial investigations have suggested a relationship between a number of genetic changes and poor prognosis for colorectal cancer patients. Kern et al. (1989) (Hole & Stern, 1988; Southall et al., 1990) . Up to 85% of colorectal and 81% of gastric carcinomas express 5T4 antigen, and analysis of the patterns of staining has indicated a correlation with metastasis (Starzynska et al., 1992 Turnbull et al. (1967) . In three patients, tumour resection was incomplete and in one patient follow-up data were unavailable, so these patients were excluded from the analysis. For the 68 patients analysed, the median age was 65 years (range 35-90), and 42 (62%) were male. Eight, 30, 21 and nine carcinomas were Dukes' stage A, B, C and D respectively. Forty-two tumours were located in the rectum; nine in the sigmoid; four, two and four in the descending, transverse and ascending colon respectively; and seven in the caecum. For further analysis these were divided into rectum and colon lesions. The colorectal tumours were predominantly moderately differentiated (46) or well differentiated (18); only four tumours were poorly differentiated. The mean time of follow-up for patients still alive was 68.5 months (the minimum being 5 years). The nine patients with Dukes' stage D disease were excluded from the survival analysis.
Immunohistochemistry Tumour samples were obtained at surgery and the tissue was immediately embedded in OCT compound, frozen in liquid nitrogen and subsequently stored at -70°C. A three-stage immunoperoxidase technique was used to detect 5T4 antigen as previously described (Starzynska et al., 1992) . Briefly, slides were incubated sequentially with 5T4 monoclonal antibody diluted 1:20 for 1 h, biotinylated rabbit anti-mouse antibodies (Dako) diluted 1:400 for 30 min and streptavidin-horseradish peroxidase (HRP)-conjugated reagent diluted 1:800 for 30min. Peroxidase was visualised using a solution of diaminobenzidine tetrahydrochloride (DAB, Sigma) in Tris-buffered saline (TBS) containing 0.03% hydrogen peroxide. When tumour cells were labelled for 5T4 antigen, there was reactivity in all or nearly all malignant cells as evidenced by congruency with cytokeratin labelling. The cellular location appeared mostly membranous. In 11 tumours there was focal reactivity. Tumours were scored by a single observer (T. Starzynska) and graded as 5T4 positive if any malignant cells exhibited such membranous staining. The distinction between tumour and stromal only or negative labelling was obvious.
Statistical analysis
The disease-free time was defined as the time to the clinical appearance of local recurrence, metastatic disease or death from cancer-related causes. The survival time was defined as the time to cancer-related death. Three patients with incomplete tumour resection and all Dukes' stage D patients were omitted from survival analysis. All patients with stage A, B and C included in the survival analysis had a curative resection (as estimated by the surgeon and pathologist). There were four non-cancer deaths which were accounted for by the analysis. Statistical analysis of survival or disease-free time was performed using the log-rank method (Peto et al., 1976 (Peto et al., , 1977 . The presence of 5T4 antigen in tumour cells was compared with tumour stage, grade, site, patients' age and sex by Fischer's exact test with a significance level of P <0.05. Age was analysed as two or four groups split by the median or quartile values. In order to test that 5T4 was acting as an independent prognostic indicator, stratified logrank analyses were performed, stratifying the data by each of the other variables in turn. Figure 1 illustrates the patterns of 5T4 antigen labelling detected by immunohistochemistry in cryostat sections of colorectal carcinomas. Table I summarises the 5T4 antigen expression in the colorectal cancers of the patients analysed in this study. There is a significant correlation between 5T4 antigen expression by malignant colorectal cells and modified Dukes' stage (P = 0.001), but not with age, sex, tumour site or grade. Figure 2 shows the overall disease-free interval and survival curves for the 5T4-positive and -negative groups.
Results
The difference is highly significant (n = 59, XI2 = 19.8, P<0.001), with 75% of 5T4-negative patients surviving 5 years compared with only 22% of the 5T4-positive group. In total, there were 8/38 cancer-related deaths in the 5T4-negative group and 15/21 in the positive group. There are significant differences in the disease-free interval and survival and the four pathological stages. For the different Dukes' stages the 5 year survivals are as follows: stage B, 73%; and stage C, 30% (n= 59, XI2= 15.4, P<0.001); there are too few Duke's A tumours for separate analysis (n = 8). There were significant differences in survival between patients older or younger than 65 years (n = 57, x,2= 10.0, P = 0.002).
There were no significant differences in disease-free interval or overall survival between males and females or between tumour sites or grades. The three patients who received chemotherapy following surgery were not long-term survivors. Stratified analysis showed that 5T4 was acting independently of each of stage, site of tumour, age or sex. aTwo patient ages unknown. CStatistically significant (P = 0.001). For example, Figure 3 shows the survival curves for the patients with Dukes' stage B and C and, although the numbers are small, there are significant differences in survival between 5T4-positive and -negative patients in both the subsets (P = 0.001 and P = 0.034 respectively). The full logrank analysis stratified by stage shows a highly significant difference in survival between 5T4-positive and -negative patients after allowing for the effect of stage (n = 59, Xi2= 9. 1, P = 0.003).
Time (months) Figure 2 Tumour 5T4 antigen-positive (n = 21) or -negative (n = 38) tumour expression in relation to survival in 68 colorectal cancer patients.
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Discussion
The principal finding of this study is that in colorectal cancer the expression of 5T4 antigen in malignant cells is associated with poorer long-term survival. To be useful, the 5T4 marker must reflect tumour behaviour in a significant and reproducible way. Seventy-eight per cent of patients with 5T4-positive tumours died of cancer within 5 years of 'curative' resectional surgery. The four long-term survivors are 'exceptions' that might be resolved with longer follow-up. For example, in a study of 1,704 cases of colorectal carcinoma by Eisenberg et al. (1982) , the proportions of patients with Dukes' B tumours surviving at 5 and 10 years were 74.4% and 65.2% respectively, and with Duke's C tumours 37.3% and 28.8% respectively.
There are other factors which may also influence the patients' outcome. For example, some 15% of the colorectal cancers exhibited focal reactivity, with areas of 5T4-positive and -negative tumour cells seen in the same section ( Figure  1c ; see also Starzynska et al., 1992) . If the acquisition of the tumour cell-associated 5T4 antigen labelling is a reflection of the multistep natural history of colorectal cancer, then such heterogeneity may be an additional consideration when assessing prognosis. Indeed, one of the 5T4-positive long-term survivor's tumour cells exhibited focal expression. Heterogeneity of tumour expression might also contribute to misassignment of 5T4-negative tumours because of unrepresentative sampling of the tumour biopsy for immunohistochemistry. This might account for the relatively short survival of eight patients with 5T4-negative carcinomas.
Clearly, there are a number of clinical, pathological and genetic variables which must interact in the natural history of colorectal cancer (Eisenberg et It is possible that the various phenotypes might reflect quantitative or qualitative differences in expression in relation to malignancy. The original rationale for defining such an oncofetal antigen was that it may have properties that function to protect the semiallogeneic fetus from immunological rejection and which allow tumour cells to evade host immunity. Alternatively, the 5T4 surface molecules may function to promote cellular adhesion, invasion or growth by acting as a specific ligand receptor. If the function of the 5T4 molecules includes facilitation of cell movement, then the low levels of expression seen in some of the basal epithelium may indicate a role in cell migration in intestinal differentiation processes. A novel cDNA encoding the core protein of the 5T4 antigen has now been isolated (Myers et al., 1994) , which will allow investigation of functional aspects of 5T4 tumour expression.
Clinical studies indicate that adjuvant chemotherapy with 5-fluorouracil either alone or in combination with levamisole may reduce the recurrence rate for patients with resected colorectal carcinoma of Dukes' stage B and C (Laurie et al., 1989; Moertel et al., 1990) . However, only 30-40% of patients benefit from such treatment. Our results suggest that immunohistochemical detection of 5T4 oncofetal antigen may provide additional prognostic discrimination and thus be helpful in identifying patients at high risk of recurrence who would benefit most from adjuvant therapy. Conversely, patients at low risk could avoid unnecessary toxicity.
